Delcath Systems FY2025 EPS Forecast Lowered by HC Wainwright

Delcath Systems, Inc. (NASDAQ:DCTH) – Investment analysts at HC Wainwright lowered their FY2025 earnings estimates for Delcath Systems in a research note issued on Wednesday, November 5th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.06 for the year, down from their prior estimate of $0.13. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ Q4 2025 earnings at ($0.06) EPS, Q2 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.27 EPS and FY2028 earnings at $1.77 EPS.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Tuesday, November 4th. The company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02. The business had revenue of $20.56 million during the quarter, compared to analysts’ expectations of $23.22 million. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%.

Several other analysts have also recently weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Delcath Systems in a report on Wednesday, October 8th. BTIG Research reissued a “buy” rating and issued a $23.00 target price on shares of Delcath Systems in a research report on Tuesday. Wall Street Zen downgraded shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Sunday, October 12th. Stephens dropped their price objective on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a report on Tuesday, October 21st. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.40.

Delcath Systems Price Performance

DCTH stock opened at $8.64 on Friday. Delcath Systems has a one year low of $8.39 and a one year high of $18.23. The stock has a market cap of $302.24 million, a price-to-earnings ratio of 172.80 and a beta of 0.81. The company has a fifty day moving average price of $10.79 and a two-hundred day moving average price of $12.28.

Institutional Trading of Delcath Systems

Institutional investors and hedge funds have recently modified their holdings of the business. Cibc World Market Inc. boosted its stake in Delcath Systems by 21.8% in the third quarter. Cibc World Market Inc. now owns 178,510 shares of the company’s stock valued at $1,919,000 after buying an additional 31,900 shares in the last quarter. Simplify Asset Management Inc. boosted its stake in shares of Delcath Systems by 144.9% in the 3rd quarter. Simplify Asset Management Inc. now owns 261,126 shares of the company’s stock valued at $2,807,000 after purchasing an additional 154,497 shares in the last quarter. Capital Advisors Wealth Management LLC boosted its stake in shares of Delcath Systems by 12.5% in the 3rd quarter. Capital Advisors Wealth Management LLC now owns 85,500 shares of the company’s stock valued at $919,000 after purchasing an additional 9,500 shares in the last quarter. Nomura Holdings Inc. bought a new stake in shares of Delcath Systems during the 2nd quarter valued at approximately $324,000. Finally, Tower Research Capital LLC TRC acquired a new position in Delcath Systems during the 2nd quarter worth approximately $40,000. 61.12% of the stock is currently owned by institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.